We are live on ! Find out more
SM

Sabby Management Portfolio holdings

AUM $45.1M
1-Year Est. Return 74.25%
This Fund
S&P 500
This Quarter Est. Return
+6.5%
1 Year Est. Return
-74.25%
3 Year Est. Return
-95.86%
5 Year Est. Return
-99.36%
10 Year Est. Return
-99.46%
AUM
$1.78B
AUM Growth
+$215M
Cap. Flow
-$396M
Cap. Flow %
-22.17%
Top 10 Hldgs %
44.5%
Holding
325
New
107
Increased
59
Reduced
54
Closed
92

Top Buys

Rank Stock Value
1
TENX icon
Tenax Therapeutics
TENX
+$13.1M
2
BPTH
Bio-Path Holdings Inc
BPTH
+$10.3M
3
OPK icon
Opko Health
OPK
+$7.29M
4
XBI icon
State Street SPDR S&P Biotech ETF
XBI
+$6.72M
5
GILD icon
Gilead Sciences
GILD
+$6.04M

Top Sells

Rank Stock Value
1
MNKD icon
MannKind Corp
MNKD
+$22.4M
2
ABUS icon
Arbutus Biopharma
ABUS
+$9.33M
3
MDVN
MEDIVATION, INC.
MDVN
+$5.53M
4
AEGR
Aegerion Pharmaceuticals
AEGR
+$4.82M
5
TEVA icon
Teva Pharmaceuticals
TEVA
+$4.69M

Sector Composition

Rank Sector Weight
1 Healthcare 10.45%
2 Energy 0.15%
3 Communication Services 0%
4 Materials 0%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
PGNX
101
DELISTED
Progenics Pharmaceuticals Inc
PGNX
$2.12M 0.12%
+517,794
New +$2.65M
NBIX icon
102
CALL
Neurocrine Biosciences
NBIX
$18.4B
$2.1M 0.12%
1,307
– –
PFE icon
103
PUT
Pfizer
PFE
$144B
$2.09M 0.12%
+685
New +$20.4K
VIRX
104
CALL
DELISTED
Viracta Therapeutics, Inc. Common Stock
VIRX
$2.08M 0.12%
15
+8
+114% +$9.3K
DYAX
105
DELISTED
DYAX CORPORATION
DYAX
$2.06M 0.12%
230,000
+93,419
+68% +$850K
UTHR icon
106
PUT
United Therapeutics
UTHR
$26.1B
$2.04M 0.11%
+217
New +$22.2K
CPXX
107
DELISTED
CELATOR PHARMACEUTICALS INC. COMMON STOCK
CPXX
$2.02M 0.11%
626,077
-53,515
-8% -$181K
MNTA
108
CALL
DELISTED
Momenta Pharmaceuticals, Inc.
MNTA
$2.01M 0.11%
1,729
-858
-33% -$14.5K
CASI
109
DELISTED
CASI Pharmaceuticals
CASI
$1.95M 0.11%
106,522
-22,471
-17% -$425K
AVNR
110
CALL
DELISTED
AVANIR PHARMACEUTICALS, INC CL A
AVNR
$1.83M 0.1%
5,000
+3,337
+201% +$12.7K
NKTR icon
111
PUT
Nektar Therapeutics
NKTR
$2.39B
$1.77M 0.1%
97
+86
+782% +$17K
RXII
112
DELISTED
GALENA BIOPHARMA INC COM
RXII
$1.77M 0.1%
+708,089
New +$1.77M
ARNA
113
PUT
DELISTED
Arena Pharmaceuticals Inc
ARNA
$1.74M 0.1%
276
-456
-62% -$30.3K
ARWR icon
114
CALL
Arrowhead Research
ARWR
$12.1B
$1.69M 0.09%
1,027
-219
-18% -$3.85K
SMLR
115
DELISTED
Semler Scientific
SMLR
$1.66M 0.09%
+318,198
New +$1.99M
INVA icon
116
PUT
Innoviva
INVA
$1.61B
$1.66M 0.09%
+666
New +$19.5K
SCTL
117
DELISTED
Societal CDMO, Inc. Common Stock
SCTL
$1.65M 0.09%
+253,989
New +$1.85M
AEGR
118
DELISTED
Aegerion Pharmaceuticals
AEGR
$1.59M 0.09%
34,420
-82,206
-70% -$4.82M
SLXP
119
PUT
DELISTED
SALIX PHARMACEUTICALS LTD DEL
SLXP
$1.53M 0.09%
+148
New +$15.2K
BIIB icon
120
PUT
Biogen
BIIB
$30.4B
$1.53M 0.09%
50
-168
-77% -$53.3K
EXEL icon
121
Exelixis
EXEL
$14.2B
$1.52M 0.09%
+429,000
New +$2.92M
CERE
122
DELISTED
CERES, INC. COMMON STOCK NEW
CERE
$1.49M 0.08%
+211,963
New +$2.21M
DRNA
123
DELISTED
Dicerna Pharmaceuticals, Inc.
DRNA
$1.46M 0.08%
+51,510
New +$1.91M
ISEE
124
PUT
DELISTED
IVERIC bio, Inc. Common Stock
ISEE
$1.43M 0.08%
+400
New +$13.5K
AVNR
125
PUT
DELISTED
AVANIR PHARMACEUTICALS, INC CL A
AVNR
$1.38M 0.08%
3,750
+486
+15% +$1.85K
3 4
5
6 7

Similar funds

CG
Circumference Group Little Rock, Arkansas $44.6M AUM 5.21% 1-Year Est. Return
OC
Optimas Capital Central, Hong Kong $44.5M AUM 24.43% 1-Year Est. Return
ICCON
Investment Counsel Company of Nevada Las Vegas, Nevada $44.5M AUM 21.97% 1-Year Est. Return
PCM
Prentice Capital Management Greenwich, Connecticut $45.7M AUM 2.65% 1-Year Est. Return
CAS
CTC Alternative Strategies Chicago, Illinois $44M AUM 43.15% 1-Year Est. Return
CM
Crestline Management Fort Worth, Texas $46.3M AUM 48.82% 1-Year Est. Return
MCMC
Matrix Capital Management Company Portsmouth, New Hampshire $46.3M AUM 114.38% 1-Year Est. Return
CTC
Corundum Trust Company Sioux Falls, South Dakota $43.8M AUM 20.07% 1-Year Est. Return

Sabby Management's Q1 2014 Portfolio in Review

As of Q1 2014, Sabby Management held 325 positions worth $1.78B, up 14% from $1.57B the previous quarter. Its ten largest holdings account for 44% of the portfolio.

Sabby Management withdrew a net $396M in Q1 2014, closing 92 positions and reducing 54 holdings. Its most notable exit was MannKind Corp, an estimated $22.4M position sold in full.

By sector, the portfolio is most concentrated in Healthcare at 10% of assets, up from 9.1% a quarter earlier, followed by Energy and Communication Services.

Against the trend, Sabby Management opened a new position in Tenax Therapeutics worth $11.8M.

  • Sabby Management's largest Q1 2014 buy was Tenax Therapeutics: 66 shares worth $11.8M.
  • Sabby Management added most to Gilead Sciences in Q1 2014, an estimated $6.04M increase.
  • Sabby Management's biggest Q1 2014 reduction was Aegerion Pharmaceuticals, cutting an estimated $4.82M.
  • Sabby Management fully exited MannKind Corp in Q1 2014, selling an estimated $22.4M.
  • Sabby Management's ten largest holdings make up 44% of its $1.78B portfolio in Q1 2014.
  • Sabby Management opened 107 new positions and closed 92 in Q1 2014.
  • Sabby Management's portfolio value rose 14% quarter-over-quarter to $1.78B.

Based on Sabby Management's 13F filing for Q1 2014, filed 14 May 2014.